<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065154</url>
  </required_header>
  <id_info>
    <org_study_id>UAB 1286</org_study_id>
    <nct_id>NCT02065154</nct_id>
  </id_info>
  <brief_title>Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis</brief_title>
  <official_title>Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess the effects of cyclophosphamide (cytoxan) in the&#xD;
      post transplant setting to prevent onset of acute graft-versus-host disease (GVHD). The&#xD;
      primary objective is to determine the incidence of grade II-IV acute GVHD following&#xD;
      Allogeneic (allo) Hematopoeitic Cell Transplant (HCT) using post-transplant cyclophosphamide&#xD;
      (cytoxan) for patients with human leukocyte antigen (HLA) matched unrelated (MUD) and&#xD;
      mismatched unrelated (MMUD) donors. Other objectives for this study will be the determination&#xD;
      of disease-free survival (DFS) and overall survival (OS) following allo HCT and assess the&#xD;
      safety of post-transplant cyclophosphamide (cytoxan) for MUD and MMUD transplantation.&#xD;
      Disease recurrence and time to recurrence in patients receiving post-transplant&#xD;
      cyclophosphamide compared to historical control without post-transplant cyclophosphamide&#xD;
      (cytoxan) will also be evaluated. Other objectives will be to determine the time of onset,&#xD;
      severity, responsiveness to treatment, organs involved of acute and chronic GVHD as well as&#xD;
      observation of Immune Reconstitution over time.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 27, 2013</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade II-IV acute GVHD</measure>
    <time_frame>Assessed 1 time per week until 100 days post transplant. Then assessed 1 time per month until 1 year post transplant.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 Year Post Transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>1 Year Post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regimen Related Toxicity</measure>
    <time_frame>100 Days Post Transplant</time_frame>
    <description>Regimen Related Toxicity will be assessed for incidence within the first 100 days of transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution</measure>
    <time_frame>Days +30, +100, +18-, +365. And as clinically indicated.</time_frame>
    <description>The rate and pattern of recovery of total lymphocytes, T cell subsets, B cells, and NK calls are evaluated by flow cytometry and are quantified and reported as percentages of total cell counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Rate</measure>
    <time_frame>2 years post-transplant</time_frame>
    <description>Relapse rate will be assessed at 2 years post-transplant</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myelofibrosis</condition>
  <condition>Severe Aplastic Anemia</condition>
  <condition>Allogeneic Transplant</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide (Cytoxan)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Disease Criteria: patients must meet diagnostic criteria of acute myeloid leukemia&#xD;
             (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic&#xD;
             lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL),&#xD;
             myelodysplastic syndrome (MDS), myelofibrosis, or severe aplastic anemia. Patients&#xD;
             will be allowed on study if they are deemed eligible for allo HCT regardless of&#xD;
             remission status.&#xD;
&#xD;
          -  Age Criteria: 19 to 65 years in age.&#xD;
&#xD;
          -  Organ Function Criteria: All organ function testing should be done within 28 days of&#xD;
             study registration.&#xD;
&#xD;
          -  Cardiac: Left ventricular ejection fraction (LVEF) ≥ 50% by MUGA (Multi Gated&#xD;
             Acquisition) scan or echocardiogram.&#xD;
&#xD;
          -  Pulmonary: FEV1 (Forced expiratory volume in 1 second) and FVC (Forced vital capacity)&#xD;
             ≥ 50% predicted, DLCO (diffusing capacity of the lung for carbon monoxide) (corrected&#xD;
             for hemoglobin) ≥ 50% of predicted.&#xD;
&#xD;
          -  Renal: The estimated creatinine clearance (CrCl) must be equal or greater than 60&#xD;
             mL/min/1.73 m2 as calculated by the Cockcroft-Gault Formula:&#xD;
&#xD;
        CrCl=(140-age) x weight(kg) x 0.85 (if female)/72 x serum creatinine (mg/dL)&#xD;
&#xD;
          -  Hepatic:&#xD;
&#xD;
               -  Serum bilirubin 1.5 upper limit of normal (ULN)&#xD;
&#xD;
               -  Aspartate transaminase (AST)/alanine transaminase (ALT) 2.5 ULN&#xD;
&#xD;
               -  Alkaline phosphatase 2.5 ULN&#xD;
&#xD;
          -  Performance status: Karnofsky ≥ 70%.,&#xD;
&#xD;
          -  Patient must be informed of the investigational nature of this study in accordance&#xD;
             with institutional and federal guidelines and have the ability to provide written&#xD;
             informed consent prior to initiation of any study-related procedures, and ability, in&#xD;
             the opinion of the principal investigator, to comply with all the requirements of the&#xD;
             study.&#xD;
&#xD;
          -  Patient has a suitable and willing HLA-8/8 matched or 6/8 mismatched (at one allele)&#xD;
             unrelated donor identified.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-compliant to medications.&#xD;
&#xD;
          -  No appropriate caregivers identified.&#xD;
&#xD;
          -  HIV1 (Human Immunodeficiency Virus-1) or HIV2 positive&#xD;
&#xD;
          -  Uncontrolled medical or psychiatric disorders.&#xD;
&#xD;
          -  Uncontrolled infections, defined as positive blood cultures within 72 hours of study&#xD;
             entry, or evidence of progressive infection by imaging studies such as chest CT scan&#xD;
             within 14 days of registration.&#xD;
&#xD;
          -  Active central nervous system (CNS) leukemia.&#xD;
&#xD;
          -  Preceding allogeneic HSCT.&#xD;
&#xD;
          -  Pregnancy or Breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Racquel D Innis-Shelton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Bone Marrow Transplantation and Cellular Therapy Program</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.uab.edu/medicine/bonemarrow/</url>
    <description>UAB Bone Marrow Transplantation and Cell Therapy Program</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 5, 2013</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Omer Jamy</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>chronic myeloid leukemia</keyword>
  <keyword>CML</keyword>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>CLL</keyword>
  <keyword>non-Hodgkin lymphoma</keyword>
  <keyword>NHL</keyword>
  <keyword>Hodgkin lymphoma</keyword>
  <keyword>HL</keyword>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>myelofibrosis</keyword>
  <keyword>severe aplastic anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

